Over a recent 10-year period, a small number of physicians with distinctive characteristics accounted for a disproportionately large number of malpractice claims, according to an analysis led by David M. Studdert at Stanford University. Approximately 1% of all physicians in their sample accounted for 32% of paid claims. Among physicians with paid claims, 84% incurred only one during the study period (accounting for 68% of all paid claims), 16% had at least two paid claims (accounting for 32% of the claims), and 4% had at least three paid claims (accounting for 12% of the claims).
Paralyzed from the waist down after a BMX accident, Steven Sanchez rolled into SuitX’s Berkeley, California, office in a wheelchair. A half-hour later he was standing and walking thanks to the Phoenix—a robotic exoskeleton now available for around $40,000.
The suit returns movement to wearers’ hips and knees with small motors attached to standard orthotics. Wearers can control the movement of each leg and walk at up to 1.1 miles per hour by pushing buttons integrated into a pair of crutches.
Men using a cellular phone for more than one hour a day double the risk of their sperm count dropping to levels too low for procreation, according researchers from the Haifa Technion and the Carmel Medical Center.
A new study conducted at the two institutions, and published Tuesday in the medical journal Reproductive BioMedicine Online, brings evidence to support a long-feared link between dropping fertility rates in men and the prevalent use of cellular phones.
For all the hype and investments in wearable devices, they have yet to deliver widespread, meaningful impact on healthcare, outside of narrow applications like measuring blood pressure and the number of steps a person walks in a day.
Count Zeb Kimmel among the skeptics, at least when it comes to solving harder problems for patients with diseases like Alzheimer’s and Parkinson’s.
En enero de 2015 Canan Dagdeviren apareció en una lista de la revista Forbes como una de las jóvenes científicas que están cambiando el mundo. El título, prestigioso puesto que situaba su nombre junto a los más brillantes investigadores del mundo, debió complacer a Dagdeviren, pero no sorprenderla. Nacida en Estambul, está acostumbrada a jalonar su trayectoria con reconocimientos. Fue la alumna más brillante de su licenciatura en Ingeniería Física, con lo que se ganó el derecho a una beca Fullbright para doctorarse en la universidad de Illinois, y actualmente es investigadora asociada en el Instituto David H Koch para la Investigación de Cáncer del MIT, uno de los centros más importantes del mundo.
Health systems around the world clearly recognize the potential of digital health: over the past decade, they have invested heavily in national e-health programs. Yet most have delivered only modest returns when measured by higher care quality, greater efficiency, or better patient outcomes.
People are more at risk of schizophrenia if they inherit genes that lead to excessive loss of healthy brain synapses during adolescence, a major US study suggests.
Houston-area biotech SonarMed has received FDA clearance to sell its non-invasive medical device that can monitor, in real-time, endotracheal tube position in newborn babies—and help guard against suffocation.
The company previously received regulatory approval for a version of the device used on adult patients since 2012. Executives didn’t disclose details on sales. “We wanted to establish the need, and interest, and then to move on to the neonate and pediatric market, where need is more urgent,” David Gunn, SonarMed’s vice president for strategy and business development, tells me
Adicet Bio is launching today with $51 million in Series A cash to make immunotherapies derived from human cells as a treatment for cancer and other diseases. Unlike experimental, personalized products using a patient’s own engineered T cells, which have had early success in blood cancer trials, Adicet wants to make “off the shelf” products, more like conventional drugs that are produced en masse.
Today, Neurotrack has announced the release of its first product, Neurotrack’s Imprint™, a digital cognitive assessment test that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline and help advance research and treatment of cognitive diseases like Alzheimer’s. The company has also revealed the private beta of Neurotrack’s cognitive health product, a personalized lifestyle program that brings together the best scientific research shown to reduce the risk of cognitive decline and improve overall cognitive health.
